32
Participants
Start Date
December 31, 2010
Primary Completion Date
October 31, 2012
Study Completion Date
October 31, 2012
Placebo
Matching placebo in capsules administered as a single oral dose.
250 mg CK-2017357
250 mg CK-2017357 in capsules administered as a single oral dose.
500 mg CK-2017357
500 mg CK-2017357 in capsules administered as a single oral dose.
West Penn Allegheny Health System, Pittsburgh
Drexel University College of Medicine, Philadelphia
Johns Hopkins, Baltimore
University of Virginia Health System, Charlottesville
The University of Kansas Medical Center, Kansas City
University of North Carolina, Chapel Hill
Duke University, Durham
Baylor College of Medicine, Houston
University of Texas Health Science Center, San Antonio
University of California - Irvine, Orange
UCSF - Fresno, Fresno
California Pacific Medical Center, San Francisco
Stanford University, Stanford
Hospital for Special Care, New Britain
Neurocare Center for Research, Newton
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Cytokinetics
INDUSTRY